BioSpace News Archive

Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and BRAVE-AA2), which found once-daily OLUMIANT

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it has completed its pre-New Drug Application meeting with the United States Food and Drug Administration for omaveloxolone for the treatment of patients with Friedreich’s ataxia and reaffirmed its plan to submit an NDA in the first quarter of 2022.

Nurix Therapeutics, Inc. today announced the appointments of Judith A. Reinsdorf and Paul M. Silva to its board of directors, effective October 1, 2021.

AngioDynamics, Inc. today announced financial results for the first quarter of fiscal year 2022, which ended August 31, 2021.

InMed Pharmaceuticals Inc. today announced that it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”).

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody, as a treatment for patients with relapsing forms of multiple sclerosis (RMS).

Braxia Scientific Corp. is pleased to report encouraging preliminary findings of a recent clinical study that suggests ketamine may be as effective as a standalone antidepressant, versus as an adjunctive therapy.

IntegriChain, delivering Life Sciences’ only comprehensive data and business process platform for market access, announced that four senior Medicaid rebate experts will present at Informa’s upcoming Medicaid Drug Rebate Program conference on validating Medicaid claims and readying for product launch.

HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, announced the appointment of Jonathan Lanfear as chief operating officer with a focus on leading and driving HiberCell’s emerging global reach.

Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced data from an interim analysis of an on-going 12-month Phase 3 open-label extension (OLE) study (Study 1601; Part 2) showing that treatment with FINTEPLA® (fenfluramine) oral solution led to a clinically meaningful and sustained reduction in drop seizures in patients with Lennox-Gastaut syndrome (LGS) on antiseizure medications (ASMs)